$NBSE can rise in the next daysContextual immersion trading strategy idea.
NeuBase Therapeutics is a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes.
The demand for shares of the company looks higher than the supply.
These and other conditions can cause a rise in the share price in the next days.
So I opened a long position from $8,13;
stop-loss — $7,60.
Information about take-profits will be later.
Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision.
Always do your own analysis before making deals. When you use any materials, do not rely on blind trust.
You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy.
If you like my content, you can subscribe to the news and receive my fresh ideas.
Thanks for being with me!
Biotech
BerGenBio $BGBIO upgraded target price to 86 NOK from ArcticSecQuote:
"Bemcentinib has shown effect against SARS-CoV-2 (coronavirus) in animal models and has been selected as the first of six drugs to be fast-tracked in the new UK initiative (ACCORD) to enter a phase 2 study directly.
Although there are many uncertainties around valuing this opportunity, we estimate the new indication adds NOK 21/share, with a new TP of NOK 86.
Read-out of the phase 2 study is expected in approx. 6 weeks. Developments will be followed closely."
Source:
www.research-tree.com
Merck - Test of Support LikelyThe lack of strength of the recent rally and the downward trend suggests a short-term test of support.
VBIV break out [$1.50 target]VBIV is breaking out of a symmetrical triangle on 15min within a much larger ascending triangle on 4hr which may be a continuation pattern off of the local price bottom. I expect to see $1.50 within next 3 trading days.
Golden Goose IPO "PPD" This IPO was just listed on FEB, 6th 2020 and will be killing it every earnings and has the potential to big a really big play in the market during these times. The chart I have posted is a 4HR time frame. Definitely one to add to your portfolio for awhile! I can see this being a GOLDEN GOOSE to get into early during these times! options plays are good on this one as well to play.
Pivot points and resistance are $26.86 / $28 / $29.37 on the 4HR time frame. The Linear reg. channel is bullish on all time frames up to the 3 min. when it becomes semi neutral.
Listed at 100% buy right now on Robinhood
NASDAQ:PPD Inc. provides drug development services to the biopharmaceutical industry, focuses on helping customers bring their new medicines to patients around the world. The firm also provides clinical development and laboratory services to pharmaceutical, biotechnology, medical device and government organizations and other industry participants. Its clinical development services include all phases of development (Phase I-IV), peri- and post-approval and site and patient access services; laboratory services offers advanced testing services, including bioanalytical, biomarker, vaccine, good manufacturing practice and central laboratory services. The company was founded by Fred Eshelma in 1985 and is headquartered in Wilmington, NC.
$IFRX can rise in the next daysContextual immersion trading strategy idea.
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in the United States and Europe.
The share price rose after good earnings. I see some preconditions the share price will continue growing.
The demand for shares of the company still looks higher than the supply.
These and other conditions can cause a rise in the share price in the next days.
So I opened a long position from $7,22;
stop-loss — $6,73.
Information about take-profits will be later.
Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision.
Always do your own analysis before making deals. When you use any materials, do not rely on blind trust.
You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy.
If you like my content, you can subscribe to the news and receive my fresh ideas.
Thanks for being with me!
TRIL: Getting ready for launchTRIL has broken up from its wedge formation and has successfully backtested the breakout zone. Price retraced 61.8% of the first impulsive leg higher and the stock now appears to be getting ready for a HUGE RUN UP. Long from here.
OGEN Long into and past earnings! Starting Today!AMEX:OGEN is going to rip into earnings then pull back right before then pop for 100% or more post earnings. Here are my price targets placed for the next week every few days starting with next Monday.
DD:
OGEN has
*1 drug for Oral Mucosis just finished Phase 2 trial, FULL data will be release on earnings call and ironically at the same time they have $15 Million worth of Warrants that will expire the day before. :) Also OGEN as obtained FDA Fast Track approval for this drug and marketing agreements completed in Europe to put it on the shelves immediately if Phase 2 data is good.
*1 drug for lowering cholesterol by 70% currently in Phase 1trial, expect results and Ph2 announcement mid/early summer.
*$21 Million cash on hand with burn rate of less than 10 Million per year.
*This Monday OGEN bought a COVID19 trial drug company with 4,000,000 shares or roughly $1 Million.
Trading in a channel, well established bases in this range over the last year or two, no need for extra funding for at least 1 year.
VBI vaccines $4 EOY Target Successful completion of the pivotal Phase 3 program for Sci-B-Vac®, on-track for submission of regulatory approval applications in the U.S., Europe, and Canada expected to begin in Q4 2020
Announcement of pan-coronavirus vaccine candidate targeting COVID-19, SARS, and MERS – human clinical study material expected to be available in Q4 2020
Expanded immunologic, tumor, and clinical data from recurrent GBM Phase 2a clinical study of VBI-1901 expected mid-year and Q4 2020
Human proof-of-concept data from Phase 1b/2a study of hepatitis B immunotherapeutic, VBI-2601, expected H2 2020
Net cash proceeds of approximately $54 million added to balance sheet from underwritten public offering in April 2020
11 Million shares bought by insider www.sec.gov
XBI Potential What is XBi?
XBI provides exposure to one of the broadest portfolios among US biotech ETFs. The fund equal-weights its portfolio, which in turn emphasizes small- and micro-caps and greatly reduces single-name risk. Thus, the weighted-average market cap is much smaller than some competitors. Unlike other funds in this segment, XBI is a pure biotech play, with relatively small pharma overlap as we see it. This highly efficient fund, which charges less than competing funds, has a history of beating its index due to revenue from securities lending. It has attracted a large asset base and trades with excellent volume. The fund’s alternative take on the space earns it a place on our Opportunities List.
Looking like we could see a pull back here or breakout.
Risk and reward is in our favor here. if it rejects, it can go to $95 area, if it breaks out, we can just stoploss for $1.
TGTXLets break $20 resistance and run up to 26-29... Very bullish on this one..
Took profits from BCRX early this AM wasn't estatic about their PR and upset they didn't give update about COVID-19 drug... Didn't make as much as i wanted to but happy to reinvest in it later
Ahrvo Daily Movers: Horizon Therapeutics-Bullish on this BiotechAbout Horizon Therapeutics
Horizon Therapeutics(ticker: HZNP) is a biopharmaceutical company that focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. It has collaboration agreements with Alliance for Lupus Research, Syneos Health, Inc., and HemoShear Therapeutics, LLC. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. HZNP was founded in 2005 and is headquartered in Dublin, Ireland.
Ahrvo Stock Rankings
Horizon Therapeutics is a top-ten ranked stock on Ahrvo, coming in 6th place (out of over 7,000+ stocks we cover) based on the most recent daily rankings. HZNP has an AhrvoScore (overall score) of 99. Over the last 3 months, Horizon has seen a slight increase in AhrvoScore, up 2 points. Momentum Score, Quality Score, Value Score, and Growth Score are top-notch, clocking in at 94, 80, 99, and 99, respectively. All four sub-scores have increased over the last 3 months. Momentum is up 5 points, Quality up 1 point, Value up 5 points, and Growth up 2 points. Furthermore, Horizon Therapeutics ranks higher than its competitors across all stock scores: Ahrvo Score 99 vs. 35, Momentum Score 94 vs. 62, Value Score 99 vs. 14, Quality Score 80 vs. 18, and Growth Score 99 vs. 42. Ahrvo’s proprietary trading signal also indicates that HZNP is currently a STRONG BUY.
Our Take
Horizon Therapeutics has performed well relative to the S&P 500 (ticker: SPY) and Nasdaq Biotechnology Index (ticker: IBB). Over the last 6 months, HZNP is up +21%, while the S&P 500 and Biotech Index have returned -8% and +10%, respectively. The company is extremely profitable with net margins of 44%. Last year they earned $573 million on $1.3 billion in revenue. Horizon Therapeutics reports Q1 earnings on Wednesday and is expected to beat analyst expectations. HZNP’s orphan drug portfolio should remain resilient and continue to perform well in the face of economic uncertainty. Orphan drugs are created for extremely rare diseases and drug recipients will need HZNP’s remedies irregardless of what happens with the broader economy. The analyst community is positive on the stock as well. Out of the 12 analysts that cover the company, 10 have HZNP rated as a strong buy (3) or buy (7), with 2 holds. Horizon Therapeutics 12-month median price target is $44.60, representing 25% upside from current levels.
-Appo Agbamu, CFA
This material is for informational purposes only. Under no circumstances should any information or materials presented be used or construed as an offer to sell, or a solicitation of an offer to buy, any securities, financial instruments, investments, or other services. Any investment made is at your sole discretion. There are many factors that you must consider when making an investment decision, including, but not limited to, product features, risks, whether or not an investment meets your investment objectives, risk tolerance, and other personalized factors. Investing in securities involves risks, and there is always the potential of losing your entire investment.
$TEVA - Weekly Chart 2020Teva's earnings May 7th - www.sec.gov
Weekly chart is flashing buy signals with the 50SMA Crossing back under the price.
Unknowns: COVID-19 impact on TEVA earnings
Decision - Wait until after earnings to get in, still to many unknowns.
The reason I like TEVA : Possible Turn-around play, looking for teva to turn net-loss to net-profit in the coming years if they continue to lower debt and start turning profit.
Earnings (loss) per share attributable to ordinary shareholders:
Basic ($)
2020 - Lower?
2019 - (0.91) even lower?
2018 - (2.35) Lower loss
2017 - (16.26) Huge loss
2016 - 0.07 Smaller profit
2015 - 1.84 Profit
Diluted ($)
2019 - (0.91)
2018 - (2.35)
2017 - (16.26)
2016 - 0.07
2015 -1.82
www.sec.gov
Quick Pump and Dump | THMODo Not Trade This! I'd personally wait for a retest around $6.90 before making my move. Might buy a few shares for fun tomorrow and see how it rolls.
For premium crypto & option signals, direct message me or @Kyer
DotcomJack | Easy Loot
$MOH tight consolidation at ATH - Long@173/Target 200 - 5/1/2020MOH (Biotech stock) has been consolidating tightly at ATH. There is clear R/S in this name despite the recent market weakness. On the 65m chart, MOH cleared the HVN above 172 and looks primed for continuation next week. Went long at the HVN break and above the intraday higher high.
Entry - 172.96
Stop Loss - 165
Target - 200
I will continue to update this post as the trade develops.
$SYBX can rise in the next daysContextual immersion trading strategy idea.
Synlogic is a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States.
The demand for shares of the company looks higher than the supply.
These and other conditions can cause a rise in the share price in the next days.
So I opened a long position from $2,32;
stop-loss — $2,15.
Information about take-profits will be later.
Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision.
Always do your own analysis before making deals. When you use any materials, do not rely on blind trust.
You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy.
If you like my content, you can subscribe to the news and receive my fresh ideas.
Thanks for being with me!
$Ghsi Retracement within triangle Ghsi looks to be retracing, imo will retrace to 0.3412. then i am looking for a bounce to go long.
Dependant on whether it is able to maintain key levels and break through the triangle.
Looking to add to my positions soon and hold until PT is hit.
Wait for SGMO to hit in the $4.50 RangeAll,
This is a GREAT stock that has an extremely clear bottom and only $7 which means options and just buy and selling is easy. Right now it is extremely obvious.
Buy in around $4 to $4.75 UNLESS it breaks this upper resistance, but even if it does there are some resistance levels $9-$11 range. So I would be careful if you are bullish where it is at now.
INCYTE Corp $INCYINCY broke the resistance with great volume. After long rally, it is maybe time to pull back. Watch for RSI
APTO Buy and Sell ZonesAPTO Buy and Sell zones on a trend reversal could be cup and handle obviously a double bottom.
If it holds this higher uptrend support and not the channel a breakout is still a buy above obviously
